Effect of Intravenous Dextrose on PONV in Patients Undergoing Gynecological Laparoscopy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to explore the relationship between intravenous infusion of dextrose during emergence from anesthesia and the incidence of PONV in patients undergoing gynecology laparoscopy (GL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preoperative Dextrose Infusion and Postoperative Nausea and Vomiting

NCT06288542

Effect of Dextrose on Postoperative Nausea and Vomiting

NOT_YET_RECRUITING NA

Dextrose Containing Fluid and the Postoperative Nausea and Vomiting in the Gynecologic Laparoscopic Surgery

NCT03139383

Postoperative Nausea and Vomiting

COMPLETED NA

A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting

NCT01123837

Postoperative Nausea and Vomiting

COMPLETED NA

Dextrose Effect on Postoperative Nausea and Vomiting (PONV)

NCT04726436

Postoperative Nausea and Vomiting

COMPLETED NA

Pre-operative 5% Dextrose Infusion & PONV

NCT05947981

Nausea, Postoperative

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Nausea and Vomiting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Triple (Participant, Care Provider, Outcomes Assessor)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Patients in the experimental group were infused intravenously with 5% dextrose (400 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.

Group Type ACTIVE_COMPARATOR

5% glucose

Intervention Type OTHER

Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.

Control group

Patients in the control group were infused intravenously with ringer lactate solution (400 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.

Group Type ACTIVE_COMPARATOR

lactated ringers

Intervention Type OTHER

Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5% glucose

Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.

Intervention Type OTHER

lactated ringers

Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

5% dextrose

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ASA I or II;
2. Performing gynecologic laparoscopic procedures under general anesthesia;

Exclusion Criteria

1. age \<18 or \>75
2. severe hypertension,diabetes mellitus, significant hepatic or renal disease
3. inability to follow protocol
4. refusal to participant

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No